AbbVie Inc. (ABBV) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$263.04

Open

$261.99

Day range

$260.98 – $264.00

Volume

3.1M

About AbbVie Inc.

Latest ABBV news

• The Target Report Annual Review—TTM August 2026 M&A Activity
  IPO & M&A · Sep 15, 2026

  The Target Report's annual review for the twelve months ending August 2026 highlights a significant uptick in mergers and acquisitions (M&A) activity, with total deal value reaching an unprecedented $2.5 trillion. This marks a 15% increase compared to the previous year, driven by a combination of favorable economic conditions, low-interest rates, and a surge in strategic consolidations across various sectors, particularly technology and healthcare. Notably, the technology sector accounted for nearly 40% of the total deal value, as companies sought to enhance their digital capabilities and expand their market reach amid ongoing digital transformation trends. Healthcare also saw robust activity, with several high-profile mergers aimed at streamlining operations and improving patient care through integrated services. The report indicates that private equity firms have played a crucial role in this M&A boom, with substantial capital raised for acquisitions, further fueling competition for targets. Market analysts suggest that this heightened M&A activity could lead to increased volatility in equity markets as companies reposition themselves for growth. Investors are advised to monitor sector-specific trends and the potential regulatory implications of large-scale consolidations, which may prompt scrutiny from antitrust authorities. Overall, the Target Report underscores a dynamic landscape where strategic acquisitions are likely to shape the future of various industries.

• ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX)
  IPO & M&A · Sep 10, 2026

  ADARx Pharmaceuticals has announced plans for an initial public offering (IPO) following a significant collaboration deal with AbbVie, which is expected to enhance its financial standing and validate its RNA therapy pipeline. The company is focusing on advancing its lead candidate, Onvuzosiran, which is currently in Phase 3 trials. This strategic partnership with AbbVie not only provides ADARx with essential funding but also positions it favorably within the competitive biopharmaceutical landscape. The collaboration with AbbVie, a major player in the pharmaceutical industry, underscores the potential of ADARx's innovative RNA therapies, which aim to address unmet medical needs. As the IPO approaches, market analysts are closely monitoring investor sentiment towards biotechnology firms, particularly those with promising clinical data and strong partnerships. The success of this IPO could signal increased interest in RNA-based therapies, potentially influencing market dynamics and investor allocations in the sector.

• There are some tremendous healthcare companies in bull market mode, says Jim Cramer
  Market Outlook · Sep 8, 2026

  Jim Cramer, the host of CNBC's "Mad Money," has highlighted a selection of healthcare companies that are currently thriving in what he describes as a bull market. Cramer emphasized that while artificial intelligence continues to capture headlines, investors should not overlook the robust performance and potential of healthcare stocks. He pointed to several firms that are not only showing strong earnings but also exhibiting resilience amid broader market fluctuations. Cramer’s analysis suggests that the healthcare sector is well-positioned for growth, driven by factors such as an aging population, increasing demand for innovative treatments, and advancements in biotechnology. This positive outlook could lead to increased investment in these companies, potentially boosting stock prices and attracting institutional interest. As investors seek to diversify their portfolios beyond tech-driven stocks, Cramer’s insights may encourage a shift towards healthcare, which could further enhance the sector's momentum in the coming months.

• Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch
  Market Outlook · Sep 7, 2026

  The ulcerative colitis market is poised for significant growth, with projections estimating its value to reach USD 15.99 billion by 2033, up from USD 10.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.7%. This expansion is largely driven by the increasing prevalence of the disease and the ongoing development of innovative therapies. Currently, the market is dominated by anti-TNF therapies, but a new wave of late-stage drug candidates is set to reshape treatment paradigms. Among the five late-stage drug candidates to watch are promising therapies that target various mechanisms of action, including integrins and JAK inhibitors. These candidates are expected to offer improved efficacy and safety profiles compared to existing treatments, which primarily include 5-aminosalicylic acid (5-ASA) therapies and corticosteroids. As these new therapies progress through Phase 3 and Phase 4 trials, their potential market entry could lead to increased competition and a shift in treatment strategies for patients with moderate to severe ulcerative colitis. The anticipated launch of these late-stage candidates is likely to impact market dynamics significantly, as healthcare providers and patients seek more effective and targeted treatment options. As the landscape evolves, pharmaceutical companies are expected to invest heavily in research and development to capitalize on the growing demand for ulcerative colitis therapies, ultimately enhancing patient outcomes and driving market growth.

• AbbVie-allied ADARx aims to go public with 3 drugs in the clinic
  IPO & M&A · Sep 5, 2026

  ADARx Pharmaceuticals, a biotechnology company allied with AbbVie, is preparing to launch an initial public offering (IPO) as it advances three drug candidates currently in clinical trials. The company focuses on developing innovative therapies for various diseases, leveraging its proprietary platform to enhance RNA-targeted treatments. The decision to go public comes at a time when the biotech sector is experiencing renewed interest from investors, particularly in companies with promising clinical pipelines. The three drugs in ADARx's portfolio target significant unmet medical needs, which could position the company favorably in the competitive biotech landscape. If successful, the IPO could provide the necessary capital to further advance its clinical programs and expand its research capabilities. Market analysts suggest that the backing of AbbVie, a major player in the pharmaceutical industry, may enhance investor confidence and attract attention to ADARx's offerings. As the IPO process unfolds, the performance of ADARx's stock could serve as a barometer for investor sentiment towards biotech firms with early-stage drug candidates.

• Pharma stocks soar as investors seek AI alternatives
  FT Companies · Aug 30, 2026

  Pharmaceutical stocks have experienced a significant surge in recent months, with many companies reaching record highs in August. This upward trend is largely attributed to a strategic shift among investors who are increasingly looking for alternatives to the volatile artificial intelligence sector. The positive momentum in the pharma industry has been further fueled by promising clinical trial results, which have instilled confidence in the potential for new drug approvals and market expansions. As investors pivot towards pharmaceuticals, the sector has become a beacon of stability amid broader market fluctuations. Analysts suggest that the robust performance of drugmakers could be indicative of a longer-term trend, as the demand for innovative therapies continues to grow. This shift not only reflects a desire for diversification but also highlights the resilience of the healthcare sector in times of economic uncertainty. With ongoing advancements in biotechnology and increased investment in research and development, pharmaceutical companies are well-positioned to capitalize on this renewed interest, potentially leading to sustained growth in stock valuations.

• AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
  Yahoo Finance · Aug 29, 2026

  As investors look ahead to 2026, the competition between AbbVie and Johnson & Johnson (J&J) presents a compelling case for healthcare stock selection. AbbVie, with a market capitalization of $258 billion, is trading at a lower valuation compared to J&J, which is known for its robust balance sheet and diversified product portfolio. AbbVie offers a dividend yield of 2.7% and has a promising pipeline with approximately 90 treatments in development, indicating potential for future growth. However, the company faces risks due to its heavy revenue concentration, primarily reliant on its flagship drug, Humira, which is facing increased competition from biosimilars. In contrast, Johnson & Johnson stands out with its long-standing reputation for stability, highlighted by a 64-year streak of dividend payments. J&J's diversified operations across pharmaceuticals, consumer health, and medical devices provide a buffer against market volatility, making it a more defensive investment during uncertain economic times. The healthcare sector has historically performed well in downturns, and J&J's strong fundamentals may appeal to risk-averse investors, especially as the S&P 500 navigates through geopolitical tensions and market fluctuations. While AbbVie’s lower valuation might attract growth-focused investors, J&J’s financial resilience and diversified offerings could make it a safer bet in a potentially turbulent market environment. As the healthcare sector continues to evolve, the choice between these two giants will depend on individual risk tolerance and investment strategy, particularly in light of ongoing market dynamics and the anticipated recovery of the S&P 500.

• Big Pharma steps up fight against counterfeit weight-loss drugs
  FT Companies · Aug 28, 2026

  Major pharmaceutical companies are intensifying their efforts to combat the growing prevalence of counterfeit weight-loss drugs in the UK, driven by soaring consumer demand for effective weight management solutions. The surge in demand has created a lucrative market for counterfeiters, prompting leading drugmakers to implement stricter measures to protect consumers and their brand integrity. These initiatives include enhanced monitoring of online sales channels, partnerships with regulatory authorities, and the development of advanced authentication technologies to distinguish genuine products from fakes. The implications for the pharmaceutical market are significant. As counterfeit products pose not only a financial risk but also a potential health hazard to consumers, the industry's proactive stance may bolster public trust in legitimate weight-loss treatments. This could lead to increased sales for reputable companies as consumers become more cautious and discerning in their purchasing decisions. Furthermore, the heightened focus on combating counterfeit drugs may spur innovation in product development and marketing strategies, as companies seek to differentiate their offerings in a crowded marketplace. Overall, the fight against counterfeit weight-loss drugs reflects broader trends in consumer protection and regulatory compliance within the pharmaceutical sector.

• THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade) (NYSE:THQ)
  Corporate Bonds · Aug 27, 2026

  THQ, a closed-end fund focusing on healthcare investments, has recently received a rating upgrade, signaling increased confidence in its ability to generate high-yield income for investors. The upgrade comes as the healthcare sector continues to demonstrate resilience amid economic uncertainties, driven by ongoing demand for medical services and innovations in pharmaceuticals. This positive assessment may attract more investors looking for stable income streams in a volatile market. The fund's strategy of investing in a diversified portfolio of healthcare stocks positions it well to capitalize on growth opportunities while providing attractive yields. As interest rates remain relatively low, fixed-income investors are increasingly seeking alternatives that offer higher returns, making THQ's offerings particularly appealing. Market analysts suggest that the rating upgrade could lead to increased inflows into the fund, potentially driving up its share price and enhancing its overall performance in the coming months.

• FAQ: The Strategic and Regulatory Logic Behind Biopharma M&A, From Deal Pricing to IND Sponsorship
  IPO & M&A · Aug 26, 2026

  The biopharmaceutical sector has witnessed a surge in mergers and acquisitions (M&A) activity, driven by a combination of strategic imperatives and regulatory considerations. Companies are increasingly looking to consolidate their portfolios to enhance research capabilities, expand market access, and accelerate the development of innovative therapies. Deal pricing has become a critical factor, with valuations often reflecting not only the current pipeline potential but also the anticipated regulatory hurdles and market dynamics. Regulatory frameworks play a significant role in shaping M&A strategies within the biopharma industry. The process of Investigational New Drug (IND) sponsorship is a key consideration for companies evaluating potential acquisitions. Firms are keenly aware that the ability to navigate the complex regulatory landscape can significantly impact the success of drug development and commercialization. As a result, acquiring companies often seek targets with established regulatory pathways or promising candidates that align with their strategic goals. Market implications of these trends are profound. Increased consolidation can lead to reduced competition, potentially impacting drug pricing and availability. Conversely, successful mergers can result in enhanced innovation, as combined resources may lead to more robust R&D efforts. Investors are closely monitoring these developments, as the outcomes of biopharma M&A activity will likely influence stock valuations and the overall health of the sector in the coming years.

All 38 articles in the app →

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen
• BMYBristol Myers Squibb